Cosunter(300436)2024-10-24 10:05Financial Performance - The company's revenue for Q3 2024 was ¥108,137,694.74, representing a 5.81% increase year-over-year, while the year-to-date revenue reached ¥326,316,366.25, up 16.67% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥34,602,162.43, a decrease of 10.38% year-over-year, with a year-to-date net profit of -¥70,639,938.31, showing a significant reduction in losses by 63.93%[2]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.2173, reflecting a 10.35% improvement compared to the same period last year[2]. - The total operating revenue for the third quarter of 2024 was CNY 326,316,366.25, an increase of 16.6% compared to CNY 279,691,831.64 in the same period last year[13]. - Net profit for Q3 2024 was CNY -73.76 million, an improvement from CNY -211.86 million in Q3 2023, indicating a reduction in losses of approximately 65.16%[15]. - The company reported a total comprehensive loss of CNY -73.76 million for Q3 2024, compared to a loss of CNY -211.86 million in Q3 2023, marking a decrease in comprehensive losses of approximately 65.16%[15]. - Basic and diluted earnings per share for Q3 2024 were both CNY -0.4435, an improvement from CNY -1.2295 in Q3 2023[15]. Cash Flow and Investments - The company reported a net cash flow from operating activities of -¥17,436,253.83 for the year-to-date, which is an 89.30% improvement compared to the same period last year[6]. - Cash flow from operating activities showed a net outflow of CNY -17.44 million, an improvement compared to CNY -163.01 million in the same period last year[17]. - The cash flow from investing activities for the year-to-date was -¥30,251,239.36, reflecting an 85.93% reduction in outflows compared to the previous year[6]. - Investment activities resulted in a net cash outflow of CNY -30.25 million, compared to CNY -214.99 million in the same period last year, showing a significant improvement[17]. - Cash inflow from financing activities was CNY 239 million, down from CNY 558.16 million in the previous year, indicating a decrease of approximately 57.25%[17]. - The net increase in cash and cash equivalents was -75,724,097.15 CNY, a decline from -26,479,555.68 CNY in the prior year[18]. Assets and Liabilities - The total assets as of September 30, 2024, were ¥1,514,126,207.11, down 6.22% from the end of the previous year, while the equity attributable to shareholders decreased by 13.68% to ¥445,843,242.15[2]. - The total assets decreased to CNY 1,514,126,207.11 from CNY 1,614,481,833.09, a decline of 6.2%[12]. - The total liabilities decreased to CNY 1,018,638,625.62 from CNY 1,045,236,873.62, a reduction of 2.5%[12]. - The company's cash and cash equivalents decreased to CNY 127,345,862.39 from CNY 202,830,792.87 at the beginning of the period, representing a decline of 37.1%[10]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,627[7]. - Fujian Aohua Group Co., Ltd. holds 22.02% of shares, totaling 35,068,651 shares, with 26,110,000 shares pledged[7]. - Ye Liqing, a natural person shareholder, holds 8.50% of shares, totaling 13,536,700 shares, with 10,152,525 shares under lock-up[7]. - Li Guoping holds 5.65% of shares, totaling 9,000,941 shares, with 3,100,000 shares frozen[7]. - Fujian Pingtan Aotai Technology Investment Center holds 5.04% of shares, totaling 8,025,000 shares, with 6,000,000 shares pledged[7]. - The total number of restricted shares at the beginning of the period was 23,720,749, with 1,175,718 shares released during the period[8]. - At the end of the period, the total number of restricted shares is 22,545,031[8]. - Li Guoping's restricted shares decreased from 7,920,649 to 6,750,706 after releasing 1,169,943 shares[8]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[8]. - The company has a significant portion of shares held by major shareholders under various restrictions, indicating a concentrated ownership structure[7]. Research and Development - Research and development expenses for the year-to-date were ¥22,866,899.17, a significant decrease of 75.21% compared to ¥92,260,063.89 in the same period last year, primarily due to the completion of the GST-HG171 project[5]. - The company completed the Phase II clinical trial of the innovative hepatitis B drug GST-HG141, achieving a HBV DNA suppression rate of 81.5% and 84.0% in high and low dose groups, respectively[9]. - The Phase IIa clinical trial of the oral surface antigen inhibitor GST-HG131 showed a maximum decrease in HBsAg levels of 1.07 log10 IU/ml, demonstrating significant efficacy compared to placebo[9]. - The company plans to continue focusing on innovation and product development, particularly in the area of new drug research and development[4].